Genentech's leukemia drug obinutuzumab shows promise in trial

02/1/2013 | American City Business Journals · OncLive

Treatment-naive patients with chronic lymphocytic leukemia who took Genentech's experimental drug GA-101, or obinutuzumab, in combination with chlorambucil, survived significantly longer without their disease worsening compared with patients who took chlorambucil alone, a late-stage trial found. Genentech plans to submit this trial's data to U.S. and European regulators for potential approval.

View Full Article in:

American City Business Journals · OncLive

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN